These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37385475)

  • 1. Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.
    Verbinnen T; Talloen W; Janssen HLA; Zoulim F; Shukla U; Vandenbossche JJ; Biermer M; De Meyer S; Lenz O
    Antiviral Res; 2023 Aug; 216():105660. PubMed ID: 37385475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Janssen HLA; Hou J; Asselah T; Chan HLY; Zoulim F; Tanaka Y; Janczewska E; Nahass RG; Bourgeois S; Buti M; Lampertico P; Lenz O; Verbinnen T; Vandenbossche J; Talloen W; Kalmeijer R; Beumont M; Biermer M; Shukla U
    Gut; 2023 Jul; 72(7):1385-1398. PubMed ID: 36697207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy.
    Verbinnen T; Hodari M; Talloen W; Berke JM; Blue D; Yogaratnam J; Vandenbossche J; Shukla U; De Meyer S; Lenz O
    J Viral Hepat; 2020 Nov; 27(11):1127-1137. PubMed ID: 32579776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.
    Verbinnen T; Tan Y; Wang G; Dehertogh P; Vergauwen K; Neefs JM; Jacoby E; Lenz O; Berke JM
    J Antimicrob Chemother; 2020 Sep; 75(9):2526-2534. PubMed ID: 32417895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
    Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
    Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    Yuen MF; Locarnini S; Lim TH; Strasser SI; Sievert W; Cheng W; Thompson AJ; Given BD; Schluep T; Hamilton J; Biermer M; Kalmeijer R; Beumont M; Lenz O; De Ridder F; Cloherty G; Ka-Ho Wong D; Schwabe C; Jackson K; Lai CL; Gish RG; Gane E
    J Hepatol; 2022 Nov; 77(5):1287-1298. PubMed ID: 35870702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.
    Berke JM; Dehertogh P; Vergauwen K; Mostmans W; Vandyck K; Raboisson P; Pauwels F
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.
    Gane EJ; Schwabe C; Berliba E; Tangkijvanich P; Jucov A; Ghicavii N; Verbinnen T; Lenz O; Talloen W; Kakuda TN; Westland C; Patel M; Yogaratnam JZ; Dragone L; Van Remoortere P
    J Antimicrob Chemother; 2022 Mar; 77(4):1102-1110. PubMed ID: 35040959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Kim MC; Jung SW; Shin JW; Park NH
    Dig Dis Sci; 2011 Apr; 56(4):1215-21. PubMed ID: 21221793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
    Gane E; Yuen MF; Kakuda TN; Ogawa T; Takahashi Y; Goeyvaerts N; Lonjon-Domanec I; Vaughan T; Schluep T; Hamilton J; Njumbe Ediage E; Hillewaert V; Snoeys J; Lenz O; Talloen W; Biermer M
    Antivir Ther; 2022 Jun; 27(3):13596535221093856. PubMed ID: 35695169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Hongthanakorn C; Chotiyaputta W; Oberhelman K; Fontana RJ; Marrero JA; Licari T; Lok AS
    Hepatology; 2011 Jun; 53(6):1854-63. PubMed ID: 21618260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
    PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of hepatitis B virus (HBV) isolated from a pediatric case of acute lymphoid leukemia, with a delayed response to antiviral treatment: a case report.
    Chen CY; Hajinicolaou C; Walabh P; Ingasia LAO; Song E; Kramvis A
    BMC Pediatr; 2022 Mar; 22(1):168. PubMed ID: 35361141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
    J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy.
    Jindal A; Vyas AK; Kumar D; Kumar G; Sharma MK; Sarin SK
    Hepatol Res; 2018 May; 48(6):451-458. PubMed ID: 29314573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
    Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
    Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.